UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus

Clinical infectious diseases, 2022-01, Vol.74 (1), p.95-104

2022

Volltextzugriff (PDF)

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

The Lancet (British edition), 2009-09, Vol.374 (9692), p.796-806

2009

Volltextzugriff (PDF)

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

The Lancet infectious diseases, 2013-07, Vol.13 (7), p.587-596

2013

Volltextzugriff (PDF)

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK

Journal of acquired immune deficiency syndromes (1999), 2013-05, Vol.63 (1), p.77

2013

Volltextzugriff (PDF)

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

Journal of acquired immune deficiency syndromes (1999), 2010-09, Vol.55 (1), p.39

2010

Volltextzugriff (PDF)

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

The New England journal of medicine, 2008-07, Vol.359 (4), p.339-354

2008

Volltextzugriff (PDF)

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

The New England journal of medicine, 2008-07, Vol.359 (4), p.355-365

2008

Volltextzugriff (PDF)

Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

Clinical infectious diseases, 2005-06, Vol.40 (11), p.1559-1585

2005

Volltextzugriff (PDF)

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America

Clinical infectious diseases, 2014-11, Vol.59 (9), p.e96-e138

2014

Volltextzugriff (PDF)

Auditing the auditors: Evidence on the recent reforms to the external monitoring of audit firms

Journal of accounting & economics, 2010-02, Vol.49 (1), p.84-103

2010

Volltextzugriff (PDF)

A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis

The Lancet infectious diseases, 2006-11, Vol.6 (11), p.742-748

2006

Volltextzugriff (PDF)

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1—Infected Patients: 156-Week Results From STARTMRK

Clinical infectious diseases, 2011-10, Vol.53 (8), p.807-816

2011

Volltextzugriff (PDF)

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Clinical infectious diseases, 2015-06, Vol.60 (12), p.1842-1851

2015

Volltextzugriff (PDF)

Prevalence of Sleep CALM nocturia factors in a male veteran population

Neurourology and urodynamics, 2024-06, Vol.43 (5), p.1127-1133

2024

Volltextzugriff (PDF)

Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy

Clinical infectious diseases, 2018-11, Vol.67 (11), p.1712-1719

2018

Volltextzugriff (PDF)

Impaired Hepatitis C Virus (HCV)-Specific Effector CD8+ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection

Journal of Virology, 2008-10, Vol.82 (20), p.9808-9822

2008

Volltextzugriff (PDF)

Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy

Journal of neuroimmunology, 2020-07, Vol.344, p.577246-577246, Article 577246

2020

Volltextzugriff (PDF)

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1429-1441

2008

Volltextzugriff (PDF)

Measurement of Human Immunodeficiency Virus p24 Antigen in Human Cerebrospinal Fluid With Digital Enzyme-Linked Immunosorbent Assay and Association With Decreased Neuropsychological Performance

Clinical infectious diseases, 2018-06, Vol.67 (1), p.137-140

2018

Volltextzugriff (PDF)

The Team Keck Treasury Redshift Survey of the GOODS-North Field

The Astronomical journal, 2004-06, Vol.127 (6), p.3121-3136

2004

Volltextzugriff (PDF)

Correlation of Human Immunodeficiency Virus Type 1 RNA Levels in Blood and the Female Genital Tract

The Journal of infectious diseases, 1999-04, Vol.179 (4), p.871-882

1999

Volltextzugriff (PDF)

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation

Journal of acquired immune deficiency syndromes (1999), 2013-04, Vol.62 (5), p.505

2013

Volltextzugriff (PDF)

Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1

Annals of internal medicine, 2015-03, Vol.162 (6), p.461

2015

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Life Sciences & Biomedicine
(85)
Humans
(80)
Adult
(63)
Female
(60)
Male
(60)
Infectious Diseases
(59)
Biological And Medical Sciences
(56)
Medical Sciences
(52)
Middle Aged
(41)
Immunology
(39)
Hiv
(37)
Human Viral Diseases
(36)
Viral Diseases
(36)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(35)
Microbiology
(33)
Hiv Infections - Drug Therapy
(30)
Human Immunodeficiency Virus
(29)
Viral Load
(27)
Aids/hiv
(21)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial

Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America

Auditing the auditors: Evidence on the recent reforms to the external monitoring of audit firms

A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1—Infected Patients: 156-Week Results From STARTMRK

Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

Prevalence of Sleep CALM nocturia factors in a male veteran population

Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy

Impaired Hepatitis C Virus (HCV)-Specific Effector CD8+ T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection

Distinct cellular immune properties in cerebrospinal fluid are associated with cognition in HIV-infected individuals initiating antiretroviral therapy

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Measurement of Human Immunodeficiency Virus p24 Antigen in Human Cerebrospinal Fluid With Digital Enzyme-Linked Immunosorbent Assay and Association With Decreased Neuropsychological Performance

The Team Keck Treasury Redshift Survey of the GOODS-North Field

Correlation of Human Immunodeficiency Virus Type 1 RNA Levels in Blood and the Female Genital Tract

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation

Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1

Suchergebnisse filtern